STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [144] CORCEPT THERAPEUTICS INC SEC Filing

Corcept officer plans $8.3M Rule 144 stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) has a notice of proposed sale under Rule 144 for up to 75,295 shares of common stock for the account of officer Roberto Wandenkolk Vieira, to be sold through Stifel Nicolaus & Company Inc. The shares include 74,999 acquired through a stock option exercise on February 1, 2024 and 296 acquired through an ESPP purchase on September 1, 2026. The notice cites an aggregate market value of $8,339,418 and 108,098,397 shares of common stock outstanding, with an approximate sale date of September 2, 2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 75,295 shares Maximum number of CORCEPT common shares covered by the Rule 144 notice
Aggregate market value $8,339,418 Aggregate market value of the 75,295 shares covered by the notice
Shares outstanding 108,098,397 shares CORCEPT common shares outstanding referenced in the Rule 144 filing
Option shares acquired 74,999 shares Shares acquired via stock option exercise on February 1, 2024 from the issuer
ESPP shares acquired 296 shares Shares acquired via ESPP purchase on September 1, 2026 from the issuer
Approximate sale date September 2, 2026 Approximate date of sale for the shares covered by the notice
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Exercise financial
"Common Stock | 02/01/2024 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
ESPP financial
"Common Stock | 09/01/2026 | ESPP | Issuer"
An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

FAQ

What is being disclosed for CORT in this Form 144 filing?
The filing discloses a proposed Rule 144 sale of up to 75,295 shares of CORCEPT THERAPEUTICS INC common stock for the account of officer Roberto Wandenkolk Vieira, to be executed through Stifel Nicolaus & Company Inc around September 2, 2026.

How many CORT shares is the insider planning to sell and what is their value?
The notice covers up to 75,295 shares of CORCEPT THERAPEUTICS INC common stock, with an indicated aggregate market value of $8,339,418 as stated in the filing.

How were the CORT shares in this Form 144 acquired?
Of the shares covered, 74,999 were acquired through a stock option exercise dated February 1, 2024 and 296 shares were acquired through an ESPP purchase on September 1, 2026, both from the issuer.

What is the reported number of CORT shares outstanding in this notice?
The notice lists 108,098,397 shares of CORCEPT THERAPEUTICS INC common stock outstanding, used as a reference figure in connection with the proposed Rule 144 sale.

Who is the broker for the planned Rule 144 sale of CORT shares?
The proposed sale of CORCEPT THERAPEUTICS INC common stock is to be executed through Stifel Nicolaus & Company Inc, which is identified as the broker in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR